- The USPTO has allowed Oramed Pharmaceuticals' (NASDAQ:ORMP) U.S. patent for the technology "Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for Producing and using Same".
- The protease inhibitors allow the insulin and other proteins to travel through the body intact.
- Shares are down 1% premarket.
Oramed nabs new patent in U.S.
Recommended For You
About ORMP Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ORMP | - | - |
Oramed Pharmaceuticals Inc. |